Quantcast

Latest Rigel Stories

2011-03-01 06:00:00

SOUTH SAN FRANCISCO, Calif., March 1, 2011 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the fourth quarter and year ended December 31, 2010. For the fourth quarter of 2010, Rigel reported a net loss of $17.2 million, or $0.33 per share, compared to a net loss of $25.1 million, or $0.48 per share, in the fourth quarter of 2009. Weighted average shares outstanding for the fourth quarter of 2010 and 2009 were 52.2 million and 51.8 million,...

2011-02-28 06:30:00

SAN FRANCISCO, Feb. 28, 2011 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, the company's chairman and chief executive officer, is scheduled to present a company overview at three investment conferences during the month of March. Details of each conference are as follows: Citi Global Health Care Conference Date: Wednesday, March 2nd at 1:30 p.m. ET Location: New York, NY Cowen and Company 31st Annual Health Care...

2011-02-09 06:30:00

SOUTH SAN FRANCISCO, Calif., Feb. 9, 2011 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, the company's chairman and chief executive officer, is scheduled to participate at two investor conferences in New York City next week. Details of the events are as follows: Tuesday, February 15 at 9:00 a.m. ET 13th Annual BIO CEO & Investor Conference Panel Topic: "Rheumatoid Arthritis: the Real Joint Problem" Tuesday, February...

2011-01-06 06:30:00

SAN FRANCISCO, Jan. 6, 2011 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, the company's chairman and chief executive officer, is scheduled to present a company overview at the JP Morgan Healthcare Conference in San Francisco, CA on Thursday, January 13th at 11:30 a.m. PST. (Logo: http://photos.prnewswire.com/prnh/20030226/RIGLLOGO) To access the live audio webcast or the subsequent archived recording, log on to www.rigel.com. Please...

2010-12-09 06:30:00

SOUTH SAN FRANCISCO, Calif., Dec. 9, 2010 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it received the Licensing Deal of the Year award from Scrip Intelligence at the Sixth Annual Scrip Awards last month. The Award, presented jointly to Rigel and AstraZeneca, recognizes the significance of the collaboration forged by the companies to develop fostamatinib (previously referred to as R788) as a novel oral treatment for rheumatoid arthritis (RA). This is...

2010-11-23 06:30:00

SOUTH SAN FRANCISCO, Calif., Nov. 23, 2010 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, the company's chairman and chief executive officer, is scheduled to present a company overview at the 22nd Annual Piper Jaffray Health Care Conference in New York on Wednesday, December 1st at 3:00 p.m. EST. To access the live audio webcast or the subsequent archived recording, log on to www.rigel.com. Please connect to Rigel's website several...

2010-11-02 06:00:00

SOUTH SAN FRANCISCO, Calif., Nov. 2, 2010 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the third quarter and nine months ended September 30, 2010. For the third quarter of 2010, Rigel reported net income of $50.4 million, or $0.97 and $0.96 per basic and diluted share, respectively, compared to a net loss of $26.7 million, or $0.70 per basic and diluted share, in the third quarter of 2009. Basic weighted average shares...

2010-10-28 06:30:00

SOUTH SAN FRANCISCO, Calif., Oct. 28 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, chairman and chief executive officer, and Raul R. Rodriguez, president and chief operating officer of Rigel, will present at two separate investor conferences in November. Details of each conference are as follows: Oppenheimer 21st Annual Healthcare Conference New York, NY November 3, 1:35 p.m. EDT Speaker: Raul R. Rodriguez...

2010-09-29 06:30:00

SOUTH SAN FRANCISCO, Calif., Sept. 29 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has earned $25 million from AstraZeneca for the fulfillment of two major milestones in the agreement the two companies have regarding the clinical development of fostamatinib (R788), a novel oral syk inhibitor. The first milestone is for initiation of the phase 3 clinical program with fostamatinib in patients with rheumatoid arthritis (RA) that was announced by...

2010-09-09 06:30:00

SOUTH SAN FRANCISCO, Calif., Sept. 9 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, the company's chairman and chief executive officer, is scheduled to present a company overview at the Stifel Nicolaus Healthcare Conference in Boston, MA on Thursday, September 16th at 9:45a.m. EDT. To access the live audio webcast or the subsequent archived recording, log on to www.rigel.com. Please connect to Rigel's website several minutes prior...


Word of the Day
penuche
  • A fudgelike confection of brown sugar, cream or milk, and chopped nuts.
'Penuche' is a variant of 'panocha,' a coarse grade of sugar made in Mexico. 'Panocha' probably comes from the Spanish 'panoja, panocha,' ear of grain.
Related